期刊
EPIGENOMICS
卷 3, 期 5, 页码 547-565出版社
FUTURE MEDICINE LTD
DOI: 10.2217/EPI.11.82
关键词
cancer; DNA methylation; epigenetics; histone modification; mouse models; personalized medicine; therapeutics
资金
- Dutch Cancer Society [NKI2009-4446, AMC2009-4457]
- NHMRC
- Susan G Komen Breast Cancer Foundation
- Prostate Cancer Foundation of Australia
- Cancer Council Victoria
- Victorian Cancer Agency
- Leukemia Foundation of Australia
- Victorian Breast Cancer Research Consortium
- Australian Rotary Health Foundation
The occurrence of epigenetic aberrations in cancer and their role in promoting tumorigenesis has led to the development of various small molecule inhibitors that target epigenetic enzymes. In preclinical settings, many epigenetic inhibitors demonstrate promising activity against a variety of both hematological and solid tumors. The therapeutic efficacy of those inhibitors that have entered the clinic however, is restricted predominantly to hematological malignancies. Here we outline the observed epigenetic aberrations in various types of cancer and the clinical responses to epigenetic drugs. We furthermore discuss strategies to improve the responsiveness of both hematological and solid malignancies to epigenetic drugs.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据